(https://www.cnbc.com/2026/07/23/eli-lilly-will-file-for-approval-of-retatrutide-obesity-drug-in-2027.html) and the market's treating it as univocal good news for the sector. But watch what's happening below the surface: GLP-1 adoption is accelerating volume while compressing net pricing across the entire healthcare stack.

Research these companies